Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
31 August 2017
E-005446-17
Question for written answer
to the Commission
Rule 130
Nicola Caputo (S&D)

 Subject:  Accessibility of innovative medicines for diabetics
 Answer(s) 

Since 2009, ‘innovative medicines’ for diabetes have come onto the European market, particularly for Type 2 diabetes mellitus (the most common form of diabetes, accounting for some 90% of cases). However, they are not equally accessible in all European Union Member States. Currently in Italy, for example, general practitioners can only prescribe treatments based on sulfonylurea — medicines which have been found to have significant side-effects on patients, including an increase in mortality from cardiovascular diseases.

In some European territories, therefore, patients with Type 2 diabetes mellitus do not have ready access to innovative medicines, which creates a situation manifestly contrary to Community principles concerning the right to health and equal treatment.

— Will the Commission take action, within the limits of its powers, to harmonise national legislation on access to ‘innovative medicines’ for diabetes, taking practical action to reduce the economic and material difficulties faced by diabetic patients in obtaining such medicines?

Original language of question: IT 
Last updated: 13 September 2017Legal notice